InNexus Biotechnology Inc.

Infobox Company
company_name = InNexus Biotechnology Inc.
company_type = Public (TSX: [http://www.tsx.com/HttpController?GetPage=QuotesLookupPage&DetailedView=DetailedPrices&Market=T&ref=quickquote&Language=en&QuoteSymbol_1=ixs&x=0&y=0 IXS] )
company_slogan = Driven By Innovation
foundation = 2001, British Columbia, Canada
location = Principal Management in Scottsdale, Arizona, United States
key_people = Jeff Morhet, Chairman and CEO Wade Brooksby, CFO Gilbert R. Gabo, Esq., Vice President of Operations and Director of Legal Affairs Thomas Kindt, Chief Scientific Officer
industry = Biotechnology
products = DXL625 (CD20) for prospective treatment of Non-Hodgkin’s Lymphoma, preclinical stage,
DXL702 (HER2/neu) for prospective treatment of breast cancer, preclinical stage.
DXLdiagnostics

DXLmouse
num_employees = 45 (2008)
homepage = http://www.ixsbio.com

[http://www.ixsbio.com/ InNexus Biotechnology, Inc.] is a drug company based in British Columbia, Canada, with principal management located in the Mayo Clinic MCCRB Building on the [http://www.mayoclinic.org/tradition-heritage/arizona-campus.html Mayo Clinic Campus] in Scottsdale, Arizona, USA. InNexus was founded in 2001 and became a publicly traded corporation in 2003 on the Toronto Stock Exchange (TSX: IXS).

They are developing what they refer to as DXL-modified antibodies, wherein certain autophilic peptides are integrated with a monoclonal antibody. The DXL-modified antibodies have been shown to have enhanced binding affinity and, as a result, greater potency for use as an improved therapeutic to fight cancer and higher signal strength for use as an improved diagnostic for detecting cancer versus an unmodified antibody.

References

*" [http://www.honionline.com/honi/index.php?option=com_content&task=view&id=965 Study: DXL625 Cross-linking System Increases Treatment Potency] ", Hermatology & Oncology News, September 14, 2007, Accessed March 2, 2008.

*" [http://www.reuters.com/article/pressRelease/idUS263081+07-Feb-2008+BW20080207 InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin's Lymphoma With Leading Marketed Product] ", Reuters, February 7, 2008, Accessed March 2, 2008.

*" [http://www.tradingmarkets.com/.site/news/Stock%20News/1044651/?hcode=relatednews Maybach Financial Adds InNexus to Watchlist] ", [http://www.tradingmarkets.com Tradingmarkets.com] , January 30, 2008, Accessed March 2, 2008.

*“ [http://www.tsx.com/en/pdf/Venture50-IXS_LS.pdf InNexus Named to TSX Venture Top 50] ”, TSX Venture Exchange Official Website, May 31, 2007, Accessed March 2, 2008.

*" [http://phoenix.bizjournals.com/phoenix/stories/2007/11/26/story7.html Momentum Builds in Valley's Cancer Research Efforts] ", [http://www.bizjournals.com/phoenix/ Phoenix Business Journal] , November 23, 2007, Accessed March 2, 2008.

*“InNexus Receiving Warm Welcome From Mayo Clinic”, Arizona Republic, September 25, 2006, Accessed March 2, 2008.